REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following February investor conferences:

SunTrust Robinson Humphrey 2018 Orphan Drug DayDate: Tuesday, February 13, 2018Location: JW Marriott Essex House, New York, NY

LEERINK Partners 7th Annual Global Healthcare ConferenceDate: Wednesday, February 14, 2018Location: Lotte New York Palace, New York, NYFireside chat: Wednesday, February 14, 2018 at 3:30 p.m. ET

A live webcast of the LEERINK fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors Natalie Wildenradt, 646-681-8192 [email protected]

Media Adam Pawluk, 202-591-4063 [email protected]

You May Also Be Interested In

• SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp
• Granite Asia Ranked No. 1 Top Multi-Asset Firm in Asia for 2026, Metaclade Research Finds
• Granite Asia Ranked No. 1 Leading Financial Firm in Singapore for 2026, Metaclade Research Finds